株式会社モダリス

Modalis uses its proprietary CRISPR-GNDM (Guide Nucleotide Directed Modulation) platform, based on technology for modifying the genome-editing enzyme CRISPR-Cas9, to pursue drug discovery against targets that have traditionally been difficult to address.